Picture of Arbutus Biopharma logo

ABUS — Arbutus Biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapMomentum Trap

Momentum

Relative Strength (%)
1m-29.73%
3m-26.76%
6m+3.37%
1yr-36.03%
Volume Change (%)
10d/3m-66.14%
Price vs... (%)
52w High-52.77%
50d MA-16.96%
200d MA-10.79%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-44.4%
Return on Equity-76.19%
Operating Margin-678.87%

Financial Summary

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Arbutus Biopharma EPS forecast chart

Profile Summary

Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
January 1st, 2018
Public Since
November 13th, 2010
No. of Shareholders
102
No. of Employees
78
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
135,269,247

ABUS Share Price Performance

Similar to ABUS

Picture of Abcam logo

Abcam

us flag iconNASDAQ Global Select Market

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amryt Pharma logo

Amryt Pharma

us flag iconNASDAQ Global Select Market

Picture of Anika Therapeutics logo

Anika Therapeutics

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email